Skip to main content

Table 4 Select adverse events among nab-paclitaxel initiators by line of therapy during the follow-up perioda,b

From: The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis

Adverse event

First line (n = 172)

Second line (n = 211)

Third or later line (n = 281)

All (N = 664)

Total nc

n

%

Total nc

n

%

Total nc

n

%

Total nc

n

%

Neutropenia

165

33

20.0

190

26

13.7

222

42

18.9

577

101

17.5

Anemia

123

39

31.7

133

31

23.3

147

36

24.5

403

106

26.3

Thrombocytopenia

163

4

2.5

199

11

5.5

264

9

3.4

626

24

3.8

Infections

152

32

21.1

184

25

13.6

242

27

11.2

578

84

14.5

Peripheral neuropathy

129

20

15.5

155

19

12.3

200

31

15.5

484

70

14.5

Asthenia

141

28

19.9

178

25

14.0

232

33

14.2

551

86

15.6

Nausea and vomiting

143

47

32.9

159

30

18.9

179

41

22.9

481

118

24.5

Diarrhea

162

9

5.6

199

7

3.5

267

16

6.0

628

32

5.1

Fluid retention

160

9

5.6

196

12

6.1

257

16

6.2

613

37

6.0

Myalgia/arthralgia

133

14

10.5

159

20

12.6

230

17

7.4

522

51

9.8

Alopecia

171

0

0

209

3

1.4

280

5

1.8

660

8

1.2

  1. aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
  2. bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period (September 30, 2012)
  3. cTotal n refers to the total number of patients without baseline events for its respective subgroup